A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis - Serenity 6294-CL-0101

开始日期2018-04-19

申办/合作机构

Astellas Pharma, Inc.

EUCTR2016-004138-12-BE / Not yet recruiting临床2期

开始日期2017-11-27

申办/合作机构

Astellas Pharma Europe Ltd.

EUCTR2016-004138-12-GB / Unknown status临床2期

开始日期2017-10-30

申办/合作机构

Astellas Pharma Europe Ltd.

100 项与 ASP-6294 相关的临床结果

登录后查看更多信息

100 项与 ASP-6294 相关的转化医学

登录后查看更多信息

100 项与 ASP-6294 相关的专利（医药）

登录后查看更多信息

项与 ASP-6294 相关的文献（医药）

2018-08-13·Expert Opinion on Pharmacotherapy3区 · 医学

Bridging pharmacotherapy and minimally invasive surgery in interstitial cystitis/bladder pain syndrome treatment

3区 · 医学

Article

作者: Papatsoris, Athanasios G. ; Dellis, Athanasios E.

INTRODUCTIONInterstitial cystitis/bladder pain syndrome (IC/BPS) is a painful and debilitating clinical entity which is challenging to diagnose and even more difficult to treat. Unfortunately, none of the existing oral and intravesical medications have been established as effective and therefore relevant research is ongoing. Areas covered: In this review, the authors present established and emerging treatment options for IC/BPS in terms of medication and minimal invasive procedures. Both American and European Urological Association Guidelines recommend multimodal behavioral techniques alongside oral (e.g. amitriptyline and pentosan polysulfate sodium) or minimally invasive treatments (e.g. dimethyl sulfoxide, botulinum toxin, chondroitin sulfate, triamcinolone, hyaluronic acid, and lidocaine). Novel treatment modalities include immunomodulating drugs, stem cell therapy, nerve growth factor, and ASP6294. Expert opinion: IC/BPS is still a pathophysiological enigma with multifactorial etiopathogenesis that may be controlled but not completely cured. Patient-tailored phenotype-directed multimodal therapy is the most promising treatment strategy. Combined phenotypic categorization with specific biomarkers could help toward better treatment.

100 项与 ASP-6294 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
间质性膀胱炎	申请上市	拉脱维亚	Astellas Pharma Europe Ltd.	2017-09-28
间质性膀胱炎	申请上市	捷克	Astellas Pharma Europe Ltd.	2017-09-28
间质性膀胱炎	申请上市	西班牙	Astellas Pharma Europe Ltd.	2017-09-28
间质性膀胱炎	申请上市	英国	Astellas Pharma Europe Ltd.	2017-09-28
间质性膀胱炎	申请上市	德国	Astellas Pharma Europe Ltd.	2017-09-28
间质性膀胱炎	申请上市	波兰	Astellas Pharma Europe Ltd.	2017-09-28
间质性膀胱炎	申请上市	匈牙利	Astellas Pharma Europe Ltd.	2017-09-28
间质性膀胱炎	申请上市	俄罗斯	Astellas Pharma Europe Ltd.	2017-09-28
间质性膀胱炎	申请上市	比利时	Astellas Pharma Europe Ltd.	2017-09-28
间质性膀胱炎	申请上市	荷兰	Astellas Pharma Europe Ltd.	2017-09-28